Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche turns to a startup in search for new breast cancer drugs, agreeing to pay $850 million upfront for Regor Pharmaceuticals' CDK inhibitor portfolio. The…
Genentech buys Regor's CDK inhibitors in an $850 million deal, acquiring rights to the next-generation CDK4/2 inhibitor RGT-419B for HR+/HER2- metastatic…
SABCS 2025 (Dec 9-12, 2025) first-in-human Phase 1a/b of GDC-4198 (RGT-419B), a next-generation CDK4/2 inhibitor, in HR+/HER2- LA/mBC progressed on prior…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Regor entered definitive purchase agreement for Genentech (Roche subsidiary) to acquire Regor's portfolio of next-generation CDK inhibitors including RGT-419B (CDK2-active) for HR+/HER2- advanced/metastatic breast cancer. $850M upfront plus development, regulatory, and commercial milestones. Positions Roche to compete against Ibrance/Verzenio/Kisqali franchise. UPDATE (reviewed 2026-06): The acquisition completed in Q4 2024 (Roche Holdings Inc. 2024 Annual Report; USD 0.9B recognized as intangible assets), and the lead asset RGT-419B was rebranded GDC-4198 (RO7840734) under Genentech. Genentech opened a randomized Phase 1b/2 trial (NCT07100106, start Oct 2025) testing GDC-4198 +/- giredestrant against abemaciclib + giredestrant in the post-CDK4/6 setting, and SABCS 2025 first-in-human data showed single-agent activity (4 confirmed PRs / 24 evaluable patients) with good tolerability - confirming the post-CDK4/6 resistance thesis that drove the deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. (this deal) | 2024 | $850M | — |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Affimed N.V. | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2016 | $910M | — |
| Genentech, Inc. (Roche Group) / OMass Therapeutics Ltd. | 2025 | $420M | — |
| Genentech, Inc. (Roche Group) / MaxCyte, Inc. | 2026 | — | — |
← Browse all deals · How we score deals
More: 2024 deals · Genentech, Inc. (Roche Group) deals · Oncology deals